Pembrolizumab and chemotherapy in high-risk, early-stage, ER

• Tác giả: Fabrice André, Aditya Bardia, Fatima Cardoso, David W Cescon, Javier Cortes, Yu Ding, Peter A Fasching, Manuel Gonzalez Fernandez, Nadia Harbeck, Rina Hui, Seock-Ah Im, Liyi Jia, Vassiliki Karantza, Zhenzhen Liu, Delphine Loirat, Heather McArthur, Joyce O'Shaughnessy, Yeon Hee Park, Gábor Rubovszky, Peter Schmid, Zhimin Shao, Laura Spring, Toshimi Takano, Melinda L Telli, Konstantinos Tryfonidis, Hiroyuki Yasojima
• Ngôn ngữ: eng
• Ký hiệu phân loại: 573.1636 *Circulatory system
• Thông tin xuất bản: United States : Nature medicine , 2025
• Bộ sưu tập: NCBI
• ID: 190788

Tóm tắt

Addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab improved outcomes in patients with high-risk, early-stage, triple-negative breast cancer. However, whether the addition of neoadjuvant pembrolizumab to chemotherapy would improve outcomes in high-risk, early-stage, estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER